Delguste, Catherine ; Université de Liège - ULiège > Département clinique des animaux de compagnie et des équidés > Département clinique des animaux de compagnie et des équidés
Lepage, Olivier M; Université de Lyon > Département Hippique
Amory, Hélène ; Université de Liège - ULiège > Département clinique des animaux de compagnie et des équidés > Médecine interne des équidés
Doucet, Michèle; Université de Montréal - UdeM > Biomédecine
Language :
French
Title :
Pharmacologie clinique des bisphosphonates : revue de littérature axée sur le tiludronate chez le cheval.
Alternative titles :
[en] linical pharmacology of bisphosphonates: literature review focused on tiludronate in horses.
AGENCE NATIONALE DU MEDICAMENT VETERINAIRE (France) Tildren. [en ligne] (2006) Adresse URL : http://www.anmv.afssa.fr/ircpweb/SpcFrame.asp? Product_Identifier=11823, consulté le 11/12/2007.
AGNELLO K.A., TRUMBLE T.N., CHAMBERS J.N., SEEWALD W., BUDSBERG S.C. Effects of zoledronate on markers of bone metabolism and subchondral bone mineral density in dogs with experimentally induced cruciate-deficient osteoarthritis. Am. J. Vet. Res., 2005, 66, 1487-1495.
ALLEN M.R., IWATA K., PHIPPS R., BURR D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone, 2006, 39, 872-879.
ALVES-ROSA F., STANGANELLI C ., CABRERA J., CYMBERKNOP D., RUBEL C., VANZULLI S., VAN ROOIJEN N., PALERMO M., ISTURIZ M.A. Rapid recovery of platelet count following administration of liposome-encapsulated clodronate in a mouse model of immune thrombocytopenia. Br. J. Haematol., 2002, 116, 357-366.
ATTENBURROW D.P., BOWRING C.S., VENNART W. Radioisotope bone scanning in horses. Equine Vet. J., 1984, 16, 121-124.
BAKAL R.S., LOVE N.E., LEWBART G.A., BERRY C.R. Imaging a spinal fracture in a Kohaku Koi (Cyprinus carpio): techniques and case history report. Vet. Radiol. Ultrasound, 1998, 39, 318-321.
BENDER T., DONATH J., BARNA I., GERGELY P., JR., POOR G. The analgesic effect of pamidronate is not caused by the elevation of beta endorphin level in Paget's disease: a controlled pilot study. Neuro Endocrinol. Lett., 2006, 27, 513-515.
BERG J., LAMB C.R., O'CALLAGHAN M.W. Bone scintigraphy in the initial evaluation of dogs with primary bone tumors. J. Am. Vet. Med. Assoc., 1990, 196, 917-920.
BONJOUR J.P., AMMANN P., BARBIER A., CAVERZASIO J., RIZZOLI R. Tiludronate: bone pharmacology and safety. Bone, 1995, 17, 473S-477S.
BOONEKAMP P.M., VAN DER WEE-PALS L.J., VAN WIJKVAN LENNEP M.M., THESING C.W., BIJVOET O.L. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner., 1986, 1, 27-39.
BOWERS J.R., DAILIANA Z.H., MCCARTHY E.F., URBANIAK J.R. Drug therapy increases bone density in osteonecrosis of the femoral head in canines. J. Surg. Orthop. Adv., 2004, 13, 210-216.
CAMARDA A.J., BUTLER W.T., FINKELMAN R.D., NANCI A. Immunocytochemical localization of gamma-carboxyglutamic acid-containing proteins (osteocalcin) in rat bone and dentin. Calcif. Tissue Int., 1987, 40, 349-355.
CARSTANJEN B., LEPAGE O.M., DETILLEUX J., DUBOEUF F., AMORY H. Use of multisite quantitative ultrasonography for noninvasive assessment of bone in horses. Am. J. Vet. Res., 2002, 63, 1464-1469.
CARSTANJEN B., DUBOEUF F., DETILLEUX J., LEPAGE O.M. Equine third metacarpal bone assessment by quantitative ultrasound and dual energy X-ray absorptiometry: an ex vivo study. J. Vet. Med. A Physiol. Pathol. Clin. Med., 2003a, 50, 42-47.
CARSTANJEN B., LEPAGE O.M., HARS O., LANGLOIS P., DUBOEUF F., AMORY H. Speed of sound measurements of the third metacarpal bone in young exercising thoroughbred racehorses. Bone, 2003b, 33, 411-418.
CHAPPARD D., MINAIRE P., PRIVAT C., BERARD E., MENDOZASARMIENTO J., TOURNEBISE H., BASLE M.F., AUDRAN M., REBEL A., PICOT C., ET AL. Effects of tiludronate on bone loss in paraplegic patients. J. Bone Miner. Res., 1995, 10, 112-118.
CHAPURLAT R.D., ARLOT M., BURT-PICHAT B., CHAVASSIEUX P., ROUX J.P., PORTERO-MUZY N., DELMAS P.D. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J. Bone Miner. Res., 2007, 22, 1502-1509.
CHAVDAROVA L., PIPERKOVA E., TSONEVSKA A., TIMCHEVA K., DIMITROVA M. Bone scintigraphy in the monitoring of treatment effect of bisphosphonates in bone metastatic breast cancer. J. Buon., 2006, 11, 499-504.
CHOI J.H., SHIN Y.L., YOO H.W. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta. J. Korean Med. Sci., 2007, 22, 209-212.
CLEZARDIN P., EBETINO F.H., FOURNIER P.G. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res., 2005, 65, 4971-4974.
COUDRY V., THIBAUD D., RICCIO B., AUDIGIE F., DIDIERLAURENT D., DENOIX J.M. Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column. Am. J. Vet. Res., 2007, 68, 329-337.
COXON F.P., THOMPSON K., ROGERS M.J. Recent advances in understanding the mechanism of action of bisphosphonates. Curr. Opin. Pharmacol., 2006, 6, 307-312.
CREMERS S.C., PILLAI G ., PA PA P O U L O S S .E . Pharmacokinetics/ pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin. Pharmacokinet., 2005, 44, 551-570.
DANNEMANN C., GRATZ K.W., RIENER M.O., ZWAHLEN R.A. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone, 2007, 40, 828-834.
DAUBINE F., LE GALL C., GASSER J., GREEN J., CLEZARDIN P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl. Cancer Inst., 2007, 99, 322-330.
DAVID P., NGUYEN H., BARBIER A., BARON R. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J. Bone Miner. Res., 1996, 11, 1498-1507.
DELGUSTE C., AMORY H., GUYONNET J., THIBAUD D., GARNERO P., DETILLEUX J., LEPAGE O.M., DOUCET M. Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1. J. Vet. Pharmacol. Ther., 2008, 31, 108-116.
DELGUSTE C., DOUCET M., AMORY H., GUYONNET J., THIBAUD D. Linearity and stationarity of the pharmacokinetics of tiludronate in horses. In : American Academy of Veterinary Pharmacology & Therapeutics 14th Biennal Symposium, Washington D.C., USA, 2005.
DELGUSTE C., DOUCET M., GABRIEL A., LEPAGE O.M., THIBAUD D., AMORY H. Assessment of a bone biopsy technique for tiludronic acid dosage in horses: a preliminary study. J. Vet. Pharmacol. Ther., 2006, 29, Suppl. 1, 299-300.
DELGUSTE C., AMORY H., DOUCET M., PICCOTCREZOLLET C., THIBAUD D., GARNERO P., DETILLEUX J., LEPAGE O.M. Pharmacological effects of tiludronate in horses after long-term immobilization. Bone, 2007, 41, 414-421.
DENOIX J.M., THIBAUD D., RICCIO B. Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial. Equine Vet. J., 2003, 35, 407-413.
DESBROSSE F. Les traitements du syndrome naviculaire. In : 10e Congrès de médecine et chirurgie équine, 11-13 décembre 2007, Genève, Suisse, 192-200.
DEVOGELAER J.P., GOEMAERE S., BOONEN S., BODY J.J., KAUFMAN J.M., REGINSTER J.Y., ROZENBERG S., BOUTSEN Y. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos. Int., 2006, 17, 8-19.
DIMEGLIO L.A., PEACOCK M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J. Bone Miner. Res., 2006, 21, 132-140.
DONABEDIAN M., DELGUSTE C., PERONA G., LEBECQUE P., DUBOEUF F., LEPAGE O.M., MARTIN-ROSSET W. Third metacarpal bone mineral density assessment in the standing horse by dual X-ray absorptiometry - Suitability, precision and accuracy. Vet. Comp. Orthop. Traumatol., 2005, 18, 26-30.
EAST L.M., STEYN P.F., DICKINSON C.E., FRANK A.A. Occult osseous metastasis of a colonic adenocarcinoma visualized with technetium tc 99m hydroxymethylene diphosphate scintigraphy in a horse. J. Am. Vet. Med. Assoc., 1998, 213, 1167-1170, 1132-1163.
EBETINO F.H. Elucidation of a pharmacophore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus Sulfur Silicon Relat. Elem., 1996, 110, 217-220.
EBRAHIMPOUR A., FRANCIS M.D. Bisphosphonate therapy in acute and chronic bone loss: Physical chemical considerations in bisphosphonate-related therapies. In : Bijvoet O., Fleisch H.A., Canfield R.E., Russell R.G.G. (Eds.), Bisphosphonate on Bones. Elsevier : Amsterdam, 1995.
FAN T.M., DE LORIMIER L.P., O'DELL-ANDERSON K., LACOSTE H.I., CHARNEY S.C. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J. Vet. Intern. Med., 2007, 21, 431-439.
FINK E., CORMIER C., STEINMETZ P., KINDERMANS C., LE BOUC Y., SOUBERBIELLE J.C. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos. Int., 2000, 11, 295-303.
FLEISCH H. Bisphosphonates in bone disease: from the laboratory to the patient. The Parthenon Publishing Group : New York, 1997, 59 p.
GARNERO P., SHIH W.J., GINEYTS E., KARPF D.B., DELMAS P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab., 1994, 79, 1693-1700.
GODFRIN B., ALVAREZ M., LAROCHE M., OLLIER S., DINGREMONT C., SAILLER L., ARLET P. Effet antalgique d'une perfusion de bisphosphonates à la phase aiguë d'un tassement vertébral ostéoporotique chez le sujet âgé. Rev. Med. Interne, 2000, 21, 1004-1005.
GRAY A.W., DAVIES M.E., JEFFCOTT L.B. Generation and activity of equine osteoclasts in vitro: effects of the bisphosphonate pamidronate (APD). Res. Vet. Sci., 2002, 72, 105-113.
GREENSPAN S.L., ROSEN H.N., PARKER R.A. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J. Clin. Endocrinol. Metab., 2000, 85, 3537-3540.
HEIKKILA P., TERONEN O., MOILANEN M., KONTTINEN Y.T., HANEMAAIJER R., LAITINEN M., MAISI P., VAN DER PLUIJM G., BARTLETT J.D., SALO T., SORSA T. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer. Drugs, 2002, 13, 245-254.
HEIKKILA P., TERONEN O., HIRN M.Y., SORSA T., TERVAHARTIALA T., SALO T., KONTTINEN Y.T., HALTTUNEN T., MOILANEN M., HANEMAAIJER R., LAITINEN M. Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate. J. Surg. Res., 2003, 111, 45-52.
HENSON F.M., DAVIES M.E., SKEPPER J.N., JEFFCOTT L.B. Localisation of alkaline phosphatase in equine growth cartilage. J. Anat., 1995, 187 (Pt 1), 151-159.
HOSTUTLER R.A., CHEW D.J., JAEGER J.Q., KLEIN S., HENDERSON D., DIBARTOLA S.P. Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia. J. Vet. Intern. Med., 2005, 19, 29-33.
HUGHES D.E., WRIGHT K.R., UY H.L., SASAKI A., YONEDA T., ROODMAN G.D., MUNDY G.R., BOYCE B.F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res., 1995, 10, 1478-1487.
IGUCHI T., MIYAKAWA Y., SAITO K., NAKABAYASHI C., NAKANISHI M., SAYA H., IKEDA Y., KIZAKI M. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int. J. Oncol., 2007, 31, 285-291.
ISHIKAWA C., MATSUDA T., OKUDAIRA T., TOMITA M., KAWAKAMI H., TANAKA Y., MASUDA M., OHSHIRO K., OHTA T., MORI N. Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Br. J. Haematol., 2007, 136, 424-432.
JACKSON B.F., GOODSHIP A.E., EASTELL R., PRICE J.S. Evaluation of serum concentrations of biochemical markers of bone metabolism and insulin-like growth factor I associated with treadmill exercise in young horses. Am. J. Vet. Res., 2003a, 64, 1549-1556.
JENSEN T.B., BECHTOLD J.E., CHEN X., SOBALLE K. Systemic alendronate treatment improves fixation of press-fit implants: a canine study using nonloaded implants. J. Orthop. Res., 2007, 25, 772-778.
KEEGAN K.G., WILSON D.A., LATTIMER J.C., TWARDOCK A.R., ELLERSIECK M.R. Scintigraphic evaluation of 99mTc-methylene diphosphonate uptake in the navicular area of horses with lameness isolated to the foot by anesthesia of the palmar digital nerves. Am. J. Vet. Res., 1996, 57, 415-421.
KHOSLA S. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res., 2007, 22, 1479-1491.
KIELY P., WARD K., BELLEMORE C.M., BRIODY J., COWELL C.T., LITTLE D.G. Bisphosphonate rescue in distraction osteogenesis: a case series. J. Pediatr. Orthop., 2007, 27, 467-471.
KOBLIK P.D., HORNOF W.J., SEEHERMAN H.J. Scintigraphic appearance of stress-induced trauma of the dorsal cortex of the third metacarpal bone in racing Thoroughbred horses: 121 cases (1978-1986). J. Am. Vet. Med. Assoc., 1988, 192, 390-395.
KUMAR V., KUMAR D., HOWMAN-GILES R.B., LITTLE D.G. Is (99m)Tc-labelled pamidronate a better agent than (99m) Tc-medronate for bone imaging? Nucl. Med. Commun., 2007, 28, 101-107.
LAMBRINOUDAKI I., CHRISTODOULAKOS G., BOTSIS D. Bisphosphonates. Ann. N. Y. Acad. Sci., 2006, 1092, 397-402.
LASSETER K.C., PORRAS A.G., DENKER A., SANTHANAGOPAL A., DAIFOTIS A. Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin. Drug Investig., 2005, 25, 107-114.
LEIN M., WIRTH M., MILLER K., EICKENBERG H.U., WEISSBACH L., SCHMIDT K., HAUS U., STEPHAN C., MEISSNER S., LOENING S.A., JUNG K. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. Eur. Urol., 2007, 52, 1381-1387.
LEPAGE O.M., FRANÇOIS R.J. Aspects microradiographiques et en microscopie de fluorescence d'une exostose expérimentale du métacarpien chez le poney Shetland et de son traitement par un bisphosphonate, l'AHPrBP (APD). Applications possibles au cheval d'arme. Ann. Med. Milit. Belg., 1989, 3, 38-44.
LEPAGE O.M., HARTMANN D.J., EICHER R., UEBELHART B., TSCHUDI P., UEBELHART D. Biochemical markers of bone metabolism in draught and warmblood horses. Vet. J., 1998, 156, 169-175.
LEPAGE O.M., CARSTANJEN B., UEBELHART D. Non-invasive assessment of equine bone: an update. Vet. J., 2001, 161, 10-22.
LIN J.H., CHEN I.W., DUGGAN D.E. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab. Dispos., 1992, 20, 473-478.
LOWING K., ASTROM E., OSCARSSON K.A., SODERHALL S., ELIASSON A.C. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. Acta Paediatr., 2007, 96, 1180-1183.
MAKKONEN N., SALMINEN A., ROGERS M.J., FRITH J.C., URTTI A., AZHAYEVA E., MONKKONEN J. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur. J. Pharm. Sci., 1999, 8, 109-118.
MASARACHIA P., WEINREB M., BALENA R., RODAN G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone, 1996, 19, 281-290.
MATHES M., JORDAN M., DOW S. Evaluation of liposomal clodronate in experimental spontaneous autoimmune hemolytic anemia in dogs. Exp. Hematol., 2006, 34, 1393-1402.
MCGUIGAN M.P., CAUVIN E., SCHRAMME M.C., PARDOE C.H., MAY S.A., WILSON A.M. A double-blind placebo-controlled trial of bisphosphonate in the treatment of navicular syndrome. In : Proceedings of the 39th British Equine Veterinary Association Congress, Birmingham, UK, 2000, 207.
MCILWRAITH C.W. Use of synovial fluid and serum biomarkers in equine bone and joint disease: a review. Equine Vet. J., 2005, 37, 473-482.
MERRELL M.A., WAKCHOURE S., LEHENKARI P.P., HARRIS K.W., SELANDER K.S. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Eur. J. Pharmacol., 2007, 570, 27-37.
MOLINUEVO M.S., BRUZZONE L., CORTIZO A.M. Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells. Eur. J. Pharmacol., 2007, 562, 28-33.
MONIER-FAUGERE M.C., GENG Z., PASCHALIS E.P., QI Q., ARNALA I., BAUSS F., BOSKEY A.L., MALLUCHE H.H. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J. Bone Miner. Res., 1999, 14, 1768-1778.
MONKKONEN H., AURIOLA S., LEHENKARI P., KELLINSALMI M., HASSINEN I.E., VEPSALAINEN J., MONKKONEN J. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol., 2006, 147, 437-445.
MONKKONEN J., SIMILA J., ROGERS M.J. Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci., 1998, 62, PL95-102.
MONTALVETTI A., BAILEY B.N., MARTIN M.B., SEVERIN G.W., OLDFIELD E., DOCAMPO R. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J. Biol. Chem., 2001, 276, 33930-33937.
MORALES-PIGA A. Tiludronate. A new treatment for an old ailment: Paget's disease of bone. Expert Opin. Pharmacother., 1999, 1, 157-170.
MURAD O.M., ARORA S., FARAG A.F., GUBER H.A. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocr. Pract., 2007, 13, 232-238.
MURAKAMI H., TAKAHASHI N., TANAKA S., NAKAMURA I., UDAGAWA N., NAKAJO S., NAKAYA K., ABE M., YUDA Y., KONNO F., BARBIER A., SUDA T. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone, 1997, 20, 399-404.
NENONEN A., CHENG S., IVASKA K.K., ALATALO S.L., LEHTIMAKI T., SCHMIDT-GAYK H., UUSI-RASI K., HEINONEN A., KANNUS P., SIEVANEN H., VUORI I., VAANANEN H.K., HALLEEN J.M. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J. Bone Miner. Res., 2005, 20, 1804-1812.
PENNISI P., PIZZARELLI G., SPINA M., RICCOBENE S., FIORE C.E. Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J. Bone Miner. Metab., 2003, 21, 402-408.
PERIS P., ALVAREZ L., MONEGAL A., GUANABENS N., DURAN M., ECHEVARRIA M., ROS I., BALLESTA A.M., MUNOZ-GOMEZ J. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy. J. Bone Miner. Metab., 2002, 20, 116-120.
PERIS P., ALVAREZ L., VIDAL S., KASPER D., LEEMING D.J., MONEGAL A., ANGELES MARTINEZ M., PONS F., GUANABENS N. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement. Calcif. Tissue Int., 2006, 79, 22-26.
PERIS P. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy. Clin. Exp. Rheumatol., 2007, 25, 206-210.
PILLAI G., GIESCHKE R., GOGGIN T., JACQMIN P., SCHIMMER R.C., STEIMER J.L. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br. J. Clin. Pharmacol., 2004, 58, 618-631.
PRICE J.S., JACKSON B., EASTELL R., GOODSHIP A.E., BLUMSOHN A., WRIGHT I., STONEHAM S., LANYON L.E., RUSSELL R.G. Age related changes in biochemical markers of bone metabolism in horses. Equine Vet. J., 1995a, 27, 201-207.
PRICE J.S., JACKSON B.F., GRAY J.A., HARRIS P.A., WRIGHT I.M., PFEIFFER D.U., ROBINS S.P., EASTELL R., RICKETTS S.W. Biochemical markers of bone metabolism in growing thoroughbreds: a longitudinal study. Res. Vet. Sci., 2001, 71, 37-44.
RAUCH F., GLORIEUX F.H. Treatment of children with osteogenesis imperfecta. Curr. Osteoporos. Rep., 2006, 4, 159-164.
RAVN P., NEUGEBAUER G., CHRISTIANSEN C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone, 2002, 30, 320-324.
REGINSTER J.Y., JEUGMANS-HUYNEN A.M., ALBERT A., DENIS D., DEROISY R., LECART M.P., FONTAINE M.A., COLLETTE J., FRANCHIMONT P. Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. Bone, 1988, 9, 349-354.
REGINSTER J.Y., LECART M.P., DEROISY R., SARLET N., DENIS D., ETHGEN D., COLLETTE J., FRANCHIMONT P. Prevention of postmenopausal bone loss by tiludronate. Lancet, 1989, 2, 1469-1471.
REGINSTER J.Y. Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone, 1992, 13, 351-354.
REGINSTER J.Y., COLSON F., MORLOCK G., COMBE B., ETHGEN D., GEUSENS P. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone: a double-blind, multiple-dosage, placebo-controlled study. Arthritis Rheum., 1992, 35, 967-974.
REGINSTER J.Y., LECART M.P., DEROISY R., ETHGEN D., ZEGELS B., FRANCHIMONT P. Paget's disease of bone treated with a five day course of oral tiludronate. Ann. Rheum. Dis., 1993, 52, 54-57.
REGINSTER J.Y., CHRISTIANSEN C., ROUX C., FECHTENBAUM J., ROUILLON A., TOU K.P. Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos. Int., 2001, 12, 169-177.
REGINSTER J.Y., GIESCHKE R. Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis. Curr. Drug Metab., 2006, 7, 827-836.
REINHOLZ G.G., GETZ B., SANDERS E.S., KARPEISKY M.Y., PADYUKOVA N., MIKHAILOV S.N., INGLE J.N., SPELSBERG T.C. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue. Breast Cancer Res. Treat., 2002, 71, 257-268.
RODRIGUEZ N., BAILEY B.N., MARTIN M.B., OLDFIELD E., URBINA J.A., DOCAMPO R. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J. Infect. Dis., 2002, 186, 138-140.
ROGERS M.J., FRITH J.C., LUCKMAN S.P., COXON F.P., BENFORD H.L., MONKKONEN J., AURIOLA S., CHILTON K.M., RUSSELL R.G. Molecular mechanisms of action of bisphosphonates. Bone, 1999, 24, 73S-79S.
ROSEN H.N., MOSES A.C., GARBER J., ILOPUTAIFE I.D., ROSS D.S., LEE S.L., GREENSPAN S.L. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif. Tissue Int., 2000, 66, 100-103.
RUMBEIHA W.K., FITZGERALD S.D., KRUGER J.M., BRASELTON W.E., NACHREINER R., KANEENE J.B., FRESE K.K. Use of pamidronate disodium to reduce cholecalciferol-induced toxicosis in dogs. Am. J. Vet. Res., 2000, 61, 9-13.
RUSSELL R.G., MUHLBAUER R.C., BISAZ S., WILLIAMS D.A., FLEISCH H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif. Tissue Res., 1970, 6, 183-196.
RUSSELL R.G. Bisphosphonates: mode of action and pharmacology. Pediatrics, 2007, 119 Suppl 2, S150-162.
SANTINI D., FRATTO M.E., VINCENZI B., LA CESA A., DIANZANI C., TONINI G. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. BioDrugs, 2004, 18, 269-278.
SANZ-RODRIGUEZ C.E., CONCEPCION J.L., PEKERAR S., OLDFIELD E., URBINA J.A. Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: kinetic and metabolic studies. J. Biol. Chem., 2007, 282, 12377-12387.
SMITH E.J., LITTLE D.G., BRIODY J.N., MCEVOY A., SMITH N.C., EISMAN J.A., GARDINER E.M. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits. J. Bone Miner. Res., 2005, 20, 1731-1741.
STEIGER R., GEYER H., PROVENCHER A., PERRON-LEPAGE M.-F., VON SALIS B., LEPAGE O.M. Equine bone core biopsy: Evaluation of collection sites using a new electric drilling machine. Equine Pract., 1999, 21, 14-21.
STEPENSKY D., KLEINBERG L., HOFFMAN A. Bone as an effect compartment: models for uptake and release of drugs. Clin. Pharmacokinet., 2003, 42, 863-881.
SURI S., MONKKONEN J., TASKINEN M., PESONEN J., BLANK M.A., PHIPPS R.J., ROGERS M.J. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate- induced gastrointestinal toxicity. Bone, 2001, 29, 336-343.
SWANSON K.M., HOHL R.J. Anticancer therapy: targeting the mevalonate pathway. Curr. Cancer Drug Targets, 2006, 6, 15-37.
TERPOS E. Biochemical markers of bone metabolism in multiple myeloma. Cancer Treat. Rev., 2006, 32 Suppl 1, 15-19.
THOMPSON K., ROGERS M.J., COXON F.P., CROCKETT J.C. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol. Pharmacol., 2006, 69, 1624-1632.
TOKUDA H., KOZAWA O., HARADA A., UEMATSU T. Tiludronate inhibits interleukin-6 synthesis in osteoblasts: inhibition of phospholipase D activation in MC3T3-E1 cells. J. Cell. Biochem., 1998, 69, 252-259.
TOMLIN J.L., STURGEON C., PEAD M.J., MUIR P. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet. Rec., 2000, 147, 129-132.
TOUSSIROT E., WENDLING D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr. Opin. Rheumatol., 2007, 19, 340-345.
VAN BEEK E., HOEKSTRA M., VAN DE RUIT M., LOWIK C., PAPAPOULOS S. Structural requirements for bisphosphonate actions in vitro. J. Bone Miner. Res., 1994, 9, 1875-1882.
VAN BEEK E.R., COHEN L.H., LEROY I.M., EBETINO F.H., LOWIK C.W., PAPAPOULOS S.E. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone, 2003, 33, 805-811.
VARELA A., LEPAGE O.M., DOUCET M., MARCOUX M., GARNERO P. Tiludronate chez le cheval: Tolérance et effets à court terme sur le métabolisme osseux. Ann. Méd. Vét., 2002, 147, 123-130.
VASIKARAN S.D. Bisphosphonates: an overview with special reference to alendronate. Ann. Clin. Biochem., 2001, 38, 608-623.
VERI A., D'ANDREA M.R., BONGINELLI P., GASPARINI G. Clinical usefulness of bisphosphonates in oncology: treatment of bone metastases, antitumoral activity and effect on bone resorption markers. Int. J. Biol. Markers, 2007, 22, 24-33.
VITTE C., FLEISCH H., GUENTHER H.L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology, 1996, 137, 2324-2333.
VOSKARIDOU E., ANAGNOSTOPOULOS A., KONSTANTOPOULOS K., STOUPA E., SPYROPOULOU E., KIAMOURIS C., TERPOS E. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial . Haematologica, 2006, 91, 1193-1202.
WALDRON D., PETTIGREW V., TURK M., TURK J., GIBSON R. Progressive ossifying myositis in a cat. J. Am. Vet. Med. Assoc., 1985, 187, 64-65.
WELLER R., LIVESEY L., MAIERL J., NUSS K., BOWEN I.M., CAUVIN E.R., WEAVER M., SCHUMACHER J., MAY S.A. Comparison of radiography and scintigraphy in the diagnosis of dental disorders in the horse. Equine Vet. J., 2001, 33, 49-58.
WILSON S., SOLOMON S.E., THORP B.H. Bisphosphonates: a potential role in the prevention of osteoporosis in laying hens. Res. Vet. Sci., 1998, 64, 37-40.
WISE L.M., WALDMAN S.D., KASRA M., CHEUNG R., BINNINGTON A., KANDEL R.A., WHITE L.M., GRYNPAS M.D. Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog. Calcif. Tissue Int., 2005, 77, 367-375.
YANG LI C., MAJESKA R.J., LAUDIER D.M., MANN R., SCHAFFLER M.B. High-dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse. Bone, 2005, 37, 287-295.
YOSHIDA M., TOKUDA H., ISHISAKI A., KANNO Y., HARADA A., SHIMUZU K., KOZAWA O. Tiludronate inhibits prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts. Mol. Cell. Endocrinol., 2005, 236, 59-66.
